Product
Oral repotrectinib
Aliases
Oral repotrectinib (TPX-0005), repotrectinib
Name
Augtyro
FDA Approved
Yes
2 clinical trials
1 organization
1 drug
4 indications
1 document
Indication
Locally Advanced Solid TumorsIndication
Metastatic Solid TumorsIndication
lymphomaIndication
Primary CNS TumorsDrug
repotrectinibClinical trial
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Status: Recruiting, Estimated PCD: 2028-02-29
Clinical trial
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 AlterationsStatus: Recruiting, Estimated PCD: 2026-09-30
Document
DailyMed Label: AugtyroOrganization
E.R. Squibb & Sons, L.L.C.